NEWSROOM
News & Stories
Newsroom
Press Releases
Agendia’s MammaPrint and BluePrint Tests to Be Highlighted at San Antonio Breast Cancer Symposium
Expert Symposium Panel Will Offer Insights Into How Functional Molecular Subtypes Can Better Individualize Treatment IRVINE, CA and AMSTERDAM, THE NETHERLANDS – New breast cancer research on Agendia’s MammaPrint® and BluePrint® genomic tests will be presented Read More
Agendia Breast Cancer Test for Molecular Subtyping Improves Match of Therapy to Patient, Study Finds
IRVINE, CA and AMSTERDAM – New data from an ongoing study indicates the BluePrint genomic test provides information about the molecular subtype of breast cancer that adds value beyond what can be learned from conventional IHC-FISH pathology testing. Read More
Agendia Board of Directors Appoints Jan Egberts, M.D., as CEO
IRVINE, CA and AMSTERDAM – Agendia, Inc., a leading molecular diagnostic company, today announced the appointment of life science industry veteran and Agendia board member Jan H. Egberts, M.D., as CEO. He replaces David Macdonald, Read More







